866-997-4948(US-Canada Toll Free)

Pediatric Neuroblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Published By :

Transparency Market Research

Published Date : Oct 2018

Category :

Pharmaceutical

No. of Pages : 143 Pages

Pediatric Neuroblastoma Treatment Market - Overview

This report by Transparency Market Research analyzes the global pediatric neuroblastoma treatment market for the period between 2018 and 2026. An in-depth market assessment has been made, which offers readers accurate analysis. Market projections have been offered in terms of value (US$ Mn). Stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various products as well as new players planning to enter this market.

The global pediatric neuroblastoma treatment market has been studied for the forecast period from 2018 to 2026. For research, 2017 has been considered as the base year and 2016 as the historical year. The market report comprises an elaborate executive summary that provides overall information about various segments of the market. The report provides a detailed competitive landscape by major players operating in this market along with their shares (value %) of the global pediatric neuroblastoma treatment market for 2017. The report also provides detailed company profiles of emerging market players operating in the global market.

The market overview section comprises impact factors such as key market dynamics including drivers, restraints, and opportunities, affecting the global pediatric neuroblastoma treatment market. These factors are likely to aid stakeholders establish a strong foothold in the global market. Furthermore, the overview section comprises market attractiveness analysis, global market analysis, and forecast of the global pediatric neuroblastoma treatment market. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and countries to identify the most attractive market.

Scope

The global pediatric neuroblastoma treatment market has been segmented based therapy type and distribution channel. In terms of therapy type, the global market has been classified into immunotherapy, chemotherapy, and others. Based on distribution channel, the global pediatric neuroblastoma treatment market has been categorized into hospital pharmacies and retail pharmacies & drug stores.

In terms of region, the global pediatric neuroblastoma treatment market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. Moreover, quantitative analysis for major countries comprising the U.S., Canada, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, and Australia & New Zealand has also been provided in the report. A detailed qualitative analysis of factors responsible for driving and restraining the global pediatric neuroblastoma treatment market in various regions has been provided in this section.

The report provides a detailed outline/blueprint of the global pediatric neuroblastoma treatment market that is expected to assist new companies establish their presence and expanding their share in the market. The report concludes with the company profile section, which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies, and recent developments.

Competitive Landscape

Major players operating in the global pediatric neuroblastoma treatment market include United Therapeutics Corporation, APEIRON Biologics AG, Baxter, Cellectar Biosciences, Inc., Pfizer, Inc., MacroGenics, Inc., and Bayer AG.

The global pediatric neuroblastoma treatment market has been segmented into:

  • Global Pediatric Neuroblastoma Treatment Market, by Therapy Type
    • Immunotherapy
    • Chemotherapy
    • Others

Global Pediatric Neuroblastoma Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmaciestores & Drug S

Global Pediatric Neuroblastoma Treatment Market, by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
  • Rest of the World

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pediatric Neuroblastoma Treatment Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1. Epidemiology Pediatric Neuroblastoma
5.2. Pipeline Analysis
5.3. Key Unmet Needs in the Pediatric Neuroblastoma Treatment Market
5.4. Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis in Neuroblastoma
5.5. Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases
5.6. Rate of Utilization of MIBG-131

6. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Therapy Type, 2016–2026
6.3.1. Immunotherapy
6.3.2. Chemotherapy
6.3.3. Others
6.4. Market Attractiveness, by Therapy Type

7. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2016–2026
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies & Drug Stores
7.4. Market Attractiveness, by Distribution Channel

8. Global Pediatric Neuroblastoma Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Rest of the World
8.3. Market Attractiveness, by Region

9. North America Pediatric Neuroblastoma Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Therapy Type, 2016–2026
9.2.1. Immunotherapy
9.2.2. Chemotherapy
9.2.3. Others
9.3. Market Value Forecast, by Distribution Channel, 2016–2026
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies & Drug Stores
9.4. Market Value Forecast, by Country, 2016–2026
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Therapy Type
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Pediatric Neuroblastoma Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Therapy Type, 2016–2026
10.2.1. Immunotherapy
10.2.2. Chemotherapy
10.2.3. Others
10.3. Market Value Forecast, by Distribution Channel, 2016–2026
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies & Drug Stores
10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Therapy Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Rest of the World Pediatric Neuroblastoma Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Therapy Type, 2016–2026
11.2.1. Immunotherapy
11.2.2. Chemotherapy
11.2.3. Others
11.3. Market Value Forecast, by Distribution Channel, 2016–2026
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies & Drug Stores
11.4. Market Attractiveness Analysis
11.4.1. By Therapy Type
11.4.2. By Distribution Channel

12. Company Profiles
12.1. United Therapeutics Corporation
12.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2. Product Portfolio
12.1.3. SWOT Analysis
12.1.4. Financial Overview
12.1.5. Strategic Overview
12.2. APEIRON Biologics AG
12.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.2.2. Product Portfolio
12.2.3. SWOT Analysis
12.2.4. Financial Overview
12.2.5. Strategic Overview
12.3. Baxter 
12.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.3.2. Product Portfolio
12.3.3. SWOT Analysis
12.3.4. Financial Overview
12.3.5. Strategic Overview
12.4. Cellectar Biosciences, Inc.
12.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.4.2. Product Portfolio
12.4.3. SWOT Analysis
12.4.4. Financial Overview
12.4.5. Strategic Overview
12.5. Pfizer, Inc.
12.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.5.2. Product Portfolio
12.5.3. SWOT Analysis
12.5.4. Financial Overview
12.5.5. Strategic Overview
12.6. MacroGenics, Inc.
12.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.6.2. Product Portfolio
12.6.3. SWOT Analysis
12.6.4. Financial Overview
12.6.5. Strategic Overview
12.7. Bayer AG
12.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.7.2. Product Portfolio
12.7.3. SWOT Analysis
12.7.4. Financial Overview
12.7.5. Strategic Overview

List of Table

Table 01: List of acronyms used in the report
Table 02: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 03: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 04: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 05: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 06: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 07: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 08: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 09: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 10: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 11: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 12: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 13: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 14: Global Pediatric Neuroblastoma Treatment Market: Pipeline Analysis
Table 15: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
Table 16: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 17: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 18: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 19: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
Table 20: North America Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 21: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
Table 23: Europe Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
Table 24: Rest of the World Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Therapy Type, 2016–2026
Table 25: Rest of the World Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026

List of Chart

Figure 01: Global Pediatric Neuroblastoma Treatment Market
Figure 02: Global Pediatric Neuroblastoma Treatment Market Size (US$ Mn), by Therapy Type, 2017
Figure 03: Global Pediatric Neuroblastoma Treatment Market Segments with Leading Market Share (%), 2017
Figure 04: Global Pediatric Neuroblastoma Treatment Market Value (US$ Mn) Forecast, 2016–2026
Figure 05: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017
Figure 06: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017
Figure 07: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Region, 2017
Figure 08: Key Industry Events
Figure 09: Porter’s Five Forces Analysis
Figure 10: Epidemiology of Neuroblastoma 
Figure 11: Epidemiology of Neuroblastoma: Numbers of Annual New Neuroblastoma Cases in Key Markets
Figure 12: Epidemiology of Neuroblastoma Key Research Findings
Figure 13: Epidemiology of Neuroblastoma, by Country
Figure 14: Epidemiology of Neuroblastoma, by Country
Figure 15: Epidemiology of Neuroblastoma, by Country
Figure 16: Key Unmet Needs in the Pediatric Neuroblastoma Treatment Market 
Figure 17: Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis to the Brain
Figure 18: Global Pediatric Neuroblastoma Treatment Market: Rate of Metastasis to the Brain
Figure 19: Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases 
Figure 20: Global Pediatric Neuroblastoma Treatment Market: Neuroblastoma Relapse/Refractory cases 
Figure 21: Global Pediatric Neuroblastoma Treatment Market: Utilization of MIBG-131
Figure 22: Global Pediatric Neuroblastoma Treatment Market: Utilization of MIBG-131
Figure 23: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
Figure 24: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
Figure 25: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Immunotherapy, 2016–2026
Figure 26: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Chemotherapy, 2016–2026
Figure 27: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Others, 2016–2026
Figure 28: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 29: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 30: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2016–2026
Figure 31: Global Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, by Retail Pharmacies & Drug Stores, 2016–2026
Figure 32: Global Pediatric Neuroblastoma Treatment Market Value Share (%), by Region, 2017 and 2026
Figure 33: Global Pediatric Neuroblastoma Treatment Market Attractiveness, by Region, 2018–2026
Figure 34: North America Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) forecast, 2016–2026
Figure 35: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Country, 2017 and 2026
Figure 36: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Country, 2018–2026
Figure 37: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
Figure 38: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
Figure 39: North America Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 40: North America Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 41: Europe Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) Forecast, 2016–2026
Figure 42: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Country/Sub-region, 2017 and 2026
Figure 43: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
Figure 44: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
Figure 45: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
Figure 46: Europe Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 47: Europe Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 48: Rest of the World Pediatric Neuroblastoma Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 49: Rest of the World Pediatric Neuroblastoma Treatment Market Value Share (%), by Therapy Type, 2017 and 2026
Figure 50: Rest of the World Pediatric Neuroblastoma Treatment Market Attractiveness, by Therapy Type, 2018–2026
Figure 51: Rest of the World Pediatric Neuroblastoma Treatment Market Value Share (%), by Distribution Channel, 2017 and 2026
Figure 52: Rest of the World Pediatric Neuroblastoma Treatment Market Attractiveness, by Distribution Channel, 2018–2026
Figure 53: United Therapeutics Corporation Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 54: United Therapeutics Corporation Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 55: United Therapeutics Corporation Breakdown of Net Sales, by Product, 2017
Figure 56: United Therapeutics Corporation Research and Development Cost (US$ Mn), 2015–2017
Figure 57: United Therapeutics Corporation: SWOT Analysis
Figure 58: MacroGenics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 59: MacroGenics, Inc. Net sales of Unituxin (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 60: MacroGenics, Inc. Net sales (US$ Mn) by key brands
Figure 61: MacroGenics, Inc. Research and Development Cost (US$ Mn), 2015–2017
Figure 62: MacroGenics, Inc.: SWOT Analysis
Figure 63: APEIRON Biologics AG: SWOT Analysis
Figure 64: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2017
Figure 65: Baxter Breakdown of Net Sales (%), by Region, 2017
Figure 66: Baxter pipeline of generic products, 2016–2020
Figure 67: Baxter: SWOT Analysis
Figure 68: Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 69: Pfizer Inc. R&D Expenses (US$ Mn), 2014–2017
Figure 70: Pfizer Inc.: SWOT Analysis
Figure 71: Cellectar Biosciences, Inc. Research and Development Cost (US$ Mn) and Y-o-Y Growth (%), 2016–2017
Figure 72: Cellectar Biosciences, Inc.: SWOT Analysis
Figure 73: Bayer Group Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
Figure 74: Bayer Group Breakdown of Net Sales (%), by Region, 2017
Figure 75: Bayer Group Breakdown of Net Sales (%), by Business Segment, 2017
Figure 76: Bayer Group: SWOT Analysis

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *